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factors, including exposure to fecally con-
taminated food or water, direct contact
with swine and potentially other animals,
and consumption of undercooked mam-
malian meats, especially organ meats [13],
may also be good candidates for HEV test-
ing. Finally, because the evidence to date
suggests that only individuals who are im-
munocompromised develop chronic HEV
viremia [4–7], testing could be limited to
these patients.
In the absence of HEV data, it is not
possible to determine the frequency of
chronic alanine aminotransferase eleva-
tions in the Swiss HIV Cohort Study at-
tributable to HEV infection. However,
both HIV and HEV are ubiquitous global
pathogens, and a current research priority
is to better understand the frequency and
clinical consequences of coinfection with
these 2 viruses.
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Reply to Kuniholm et al
To the Editor—We thank Kuniholm et
al [1] for their interest in our study on the
incidence and risk factors for chronic el-
evation of alanine aminotransferase (ALT)
levels in human immunodeficiency virus
(HIV)–infected persons without hepatitis
B or C virus coinfection [2]. They suggest
that chronic hepatitis virus E (HEV) in-
fection should be considered in the dif-
ferential diagnosis in this patient group.
We indeed did not look for HEV as a cause
for chronic ALT elevation. However, the
prevalence of HEV infection is very low
in our study population, as reported at the
Conference on Retroviruses and Oppor-
tunistic Infections by investigators of the
Swiss HIV Cohort Study [3]. In this study,
Swiss HIV Cohort Study participants with
chronic elevated ALT values and no hep-
atitis B and C infection were screened for
positive anti-HEV immunoglobulin G in
the latest stored plasma sample. In HEV-
seropositive subjects, HEV polymerase
chain reaction was performed on a plasma
sample stored 3 months prior to, at the
time of, and 3 months after the first ele-
vated ALT value. Among 735 patients with
chronic ALT elevation, 19 (2.6%) were
HEV seropositive. At the time of ALT el-
evation, HEV polymerase chain reaction
results were positive in only 1 of these 19
patients.
Whether tests to detect HEV are indi-
cated among HIV-infected persons with
chronic ALT elevation in the absence of
hepatitis B or C virus coinfection or other
causes of chronic hepatitis must depend
on the local epidemiology of HEV infec-
tion and the travel history of individual
patients. Because of its low prevalence in
our study population, we do not expect
that the omission of HEV serology or mo-
lecular tests had a relevant influence on
the results of our study.
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Figure 1. Efavirenz (week 0) and nevirapine (weeks 2–12) plasma concentrations during the switch from efavirenz to nevirapine (for 18 patients).
The box plot shows a comparison of the plasma concentrations, with the upper and lower edges of the boxes representing upper and lower quartiles,
respectively. Lines extending above and below the boxes represent the highest and lowest values, respectively. Circles represent outliers. Plus signs
represent the mean values of the nevirapine plasma levels, and the small white square inside the first interquartile range (IQR) box represents the
mean value of the efavirenz plasma level. The horizontal line within each IQR box respresents the median value of the nevirapine or efavirenz plasma
level.
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Pharmacokinetics
of the Treatment Switch
from Efavirenz to Nevirapine
To the Editor—Because of its potency,
easy dosing (1 tablet per day), and rela-
tively favorable adverse-effect profile, efa-
virenz (EFV) is one of the most widely
studied antiretroviral agents for the treat-
ment of human immunodeficiency virus
infection. The most common symptoms
after initiating EFV include neuropsychi-
atric adverse effects. Other adverse effects
include rash, gynecomastia, teratogenicity,
fat redistribution, and dyslipidemia. EFV
toxicity may require a switch to nevirapine
(NVP), a safe and effective alternative [1–
4], but whether NVP should be started at
200 or 400 mg per day remains unclear
[5]. EFV increases the metabolism of other
coadministered drugs that are metabolized
by the cytochrome P450, such as metha-
done, voriconazole, and NVP. Conse-
quently, the NVP dose escalation may not
be justified in the presence of EFV. The
dose-effect relationship between steady-
state plasma EFV levels and subsequent
enzyme induction has not been studied.
The study by Parienti et al [3] was a pro-
spective randomized controlled trial eval-
uating the impact on low-density lipopro-
tein cholesterol of switching from EFV to
NVP in case of EFV-associated dyslip-
idemia. This post hoc analysis aimed to
describe the pharmacokinetics of the
steady-state plasma NVP level during the
switch from EFV and identify factors as-
sociated with suboptimal NVP plasma
levels.
EFV was randomly switched to NVP in
18 of 37 white patients. NVP was intro-
duced at 200 mg per day for 14 days, fol-
lowed by 400 mg twice per day with in-
tense pharmacokinetic sampling. The
drugs’ steady-state plasma levels were de-
termined in a central laboratory at the end
of the study. The steady-state plasma EFV
level at week 0 and the steady-state plasma
NVP levels at weeks 2, 4, 6, 8, and 12 were
plotted by use of box plots. First, we used
linear regression to assess the correlation
between the steady-state plasma EFV level
at week 0 and the steady-state plasma NVP
level at week 2. Second, we modeled the
steady-state plasma NVP level using a
mixed model, including age, sex, weight,
baseline steady-state plasma EFV level,
NVP dosage (200 mg per day vs 400 mg
per day), and time as potential predictors.
A higher steady-state plasma NVP level
at week 2 was significantly and positively
correlated with a higher steady-state
plasma EFV level at week 0 ( ;rp 0.54
). As shown in Figure 1, there wereP ! .03
7 of 18 patients who had a steady-state
plasma NVP level below 3000 ng/mL at
week 2 (lower than the recommended
limit for antiviral activity), and 5 of these
7 patients subsequently regained a thera-
peutic steady-state plasma NVP level when
treated with an NVP dosage of 400 mg
per day. Only baseline steady-state plasma
